Glucocorticoids Increase Fracture Risk and Fracture Prevalence Independently from Bone Mineral Density and Clinical Risk Factors: Results from the Gliwice Osteoporosis (GO) Study

Abstract

The aim of the study was to establish the influence of glucocorticoids (GC) on fracture risk, probability, and prevalence. A set of 1548 postmenopausal women were divided into study group – treated with GC (n=114, age 66.48±7.6 years) and controls (n=1434, age 66.46±6.83 years). Data on clinical risk factors for osteoporosis and fractures were collected. Hip bone densitometry was performed using a device Prodigy (GE, USA). Fracture probability was established by FRAX, and fracture risk by Garvan algorithm and POL-RISK. Fracture risk and fracture probability were significantly greater for GC-treated women in comparison to controls. In the study group, there were 24, 3, 24, and 6 fractures noted at spine, hip, forearm, and arm, respectively. The respective numbers of fractures reported in controls at those skeletal sites were: 186, 23, 240, and 25. The use of GCs increased significantly prevalence of all major, spine and arm fractures. Also the number of all fractures was affected by GC use. Following factors significantly increased fracture probability: age (OR 1.04 per each year; 95% CI: 1.03–1.06), GC use (OR 1.54; 95% CI: 1.03–2.31), falls (OR 2.09; 95% CI: 1.60–2.73), and FN T-score (OR 0.62 per each unit; 95% CI: 0.54–0.71). In conclusion, in patients treated with GCs the fracture risk, probability, and prevalence were increased. This effect was evident regardless of whether GC therapy is included in the algorithm as a risk factor (FRAX, POL-RISK) or not taken into consideration (Garvan nomogram).

Key words

fracture prevalence - fracture risk - fracture probability - glucocorticoids

Publication History

Received: 24 August 2021

Accepted after revision: 15 November 2021

Article published online:
05 January 2022

• References

• 1 Adler RA, Curtis JR, Saag K. et al. Glucocorticoid-induced osteoporosis. 3rd ed. San Diego: Elsevier-Academic Press; 2008
• 2 Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine 2018; 61: 7-16
• 3 Mazzantini M, Torre C, Miccoli M. et al. Adverse events during long term low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol 2012; 39: 552-557
• 4 Majumdar SR, Morin SN, Lix LM. et al. Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study. Osteoporos Int 2013; 24: 2493-2498
• 5 Ioannidis G, Pallan S, Papaionannou A. et al. CaMos research group. Glucocorticoids predict 10-year fragility fracture risk in a population-based ambulatory cohort of men and women: Canadian multicentre osteoporosis study (CaMos). Arch Osteoporos 2014; 8: 169
• 6 Amiche MA, Albaum JM, Tadrous M. et al. Fracture risk in oral glucorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int 2016; 27: 1709-1718
• 7 Balasubramanian A, Wade SW, Adler RA. et al. Glucocorticoid exposure and fracture risk in a cohort of US patients with selected conditions. J Bone Miner Res 2018; 33: 1881-1888
• 8 Robinson DE, van Staa TP, Dennison EM. et al. The limitations of using simple definitions of glucocorticoid exposure to predict fracture risk: a cohort study. Bone 2018; 117: 83-90
• 9 Chang YP, Lai CH, Lin CY. et al. Mortality and vertebral fracture risk associated with long-term oral steroid use in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Chron Respir Dis 2019; 16: 1-7
• 10 Che H, Breuil V, Cortet B. et al. Vertebral fractures cascade: potential causes and risk factors. Osteoporos Int 2019; 30: 555-563
• 11 Kanis JA, Johnell O, Oden A. et al. FRAX^TM and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19: 385-397
• 12 Adamczyk P, Werner A, Bach M. et al. Risk factors for fractures identified in the algorithm developed in 5-year follow-up of postmenopausal women from RAC-OST-POL study. J Clin Densitom 2018; 21: 213-219
• 13 Leib ES, Saag KG, Adachi JD. et al. Official positions for FRAX(®) clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX(®) of the 10 year risk of fracture from joint official positions development conference of the international society for clinical densitometry and international osteoporosis foundation on FRAX(®). J Clin Densitom 2011; 14: 212-219
• 14 Cheng TT, Lai HM, Yu SF. et al. The impact of low-dose glucocorticoids on disease activity, bone mineral density, fragility fractures, and 10-year probability of fractures in patients with rheumatoid arthritis. J Investig Med 2018; 66: 1004-1007
• 15 Pluskiewicz W, Adamczyk P, Drozdzowska B. The significance of height loss in postmenopausal women. The results from GO Study. Int J Clin Pract 2021; 75: e14009
• 16 Pluskiewicz W, Adamczyk P, Drozdzowska B. Low dietary calcium intake does not modify fracture risk but increases falls frequency: the results of GO Study. Endokrynol Pol 2021; 72: 198-201 DOI: 10.5603/EP.a2021.0021.
• 17 Pluskiewicz W, Adamczyk P, Drozdzowska B. Height loss in postmenopausal women-do we need more for fracture risk assessment? Results from the GO Study. Osteoporos Int 2021; 32: 2043-2049
• 18 Nguyen ND, Frost SA, Center JR. et al. Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int 2007; 18: 1109-1117
• 19 Nguyen ND, Frost SA, Center JR. et al. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 2008; 19: 1431-1434
• 20 Drozdzowska B. Skeletal status assessed by quantitative ultrasound at the calcaneus in females with bronchial asthma on prolonged corticosteroid therapy. Maturitas 2005; 51: 386-392
• 21 Drozdzowska B. Quantitative ultrasound at the calcaneus in corticosteroids-treated male patients with bronchial asthma. Ultrasound in Med and Biol 2004; 30: 1057-1061